These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9122732)

  • 1. Treatment of malignant melanoma with interleukin-2.
    Philip PA; Flaherty L
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S32-8. PubMed ID: 9122732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.
    Legha SS
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S39-43. PubMed ID: 9122733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R; Rosenberg SA
    J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
    Keilholz U; Stoter G; Punt CJ; Scheibenbogen C; Lejeune F; Eggermont AM
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S22-8. PubMed ID: 9457389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
    Rosenberg SA; Mulé JJ
    Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of interleukin-2 in cancer therapy.
    Kohler PC; Sondel PM
    Cancer Surv; 1989; 8(4):861-73. PubMed ID: 2701732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant interleukin-2: a biological response modifier.
    Kintzel PE; Calis KA
    Clin Pharm; 1991 Feb; 10(2):110-28. PubMed ID: 2009728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-2 in the treatment of malignant melanoma.
    Philip PA
    Expert Opin Investig Drugs; 1998 Mar; 7(3):361-71. PubMed ID: 15991978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of metastasized malignant melanoma].
    Kamanabrou D
    Praxis (Bern 1994); 2001 Mar; 90(10):391-6. PubMed ID: 11305184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2.
    Rosenberg SA; Lotze MT; Muul LM; Leitman S; Chang AE; Vetto JT; Seipp CA; Simpson C
    Surgery; 1986 Aug; 100(2):262-72. PubMed ID: 3526604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of primary leptomeningeal melanoma to intrathecal recombinant interleukin-2. A case report.
    Fathallah-Shaykh HM; Zimmerman C; Morgan H; Rushing E; Schold SC; Unwin DH
    Cancer; 1996 Apr; 77(8):1544-50. PubMed ID: 8608541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunotherapy of malignant melanoma].
    Flageul B; Miclea JM; Bensussan A; Degos L
    Pathol Biol (Paris); 1990 Oct; 38(8):881-2. PubMed ID: 2274397
    [No Abstract]   [Full Text] [Related]  

  • 16. Lessons from the clinical trials of interleukin-2.
    Parkinson DR
    Nat Immun Cell Growth Regul; 1990; 9(4):242-52. PubMed ID: 2215513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-2: use in solid tumors.
    Bukowski RM; McLain D; Olencki T; Budd GT; Murthy SA
    Stem Cells; 1993 Jan; 11(1):26-32. PubMed ID: 8457777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [High-dose Roncoleukin in patients with disseminated cutaneous melanoma: a phase 1 study].
    Moiseenko VM; Novik AV; Orlova RV; Protsenko SA; Mikhaĭlichenko TD; Semenova AI; Tiukavina NV
    Vopr Onkol; 2005; 51(5):546-9. PubMed ID: 16756008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness of treatment with transfer of autologous or allogenic LAK cells combined with rIL-2 in 121 patients with malignant pleural effusion].
    Liu X
    Zhonghua Zhong Liu Za Zhi; 1993 May; 15(3):205-8. PubMed ID: 8261867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
    Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.